Sulis Therapeutics ApS: Financial statements 2024
CVR: 44445832
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Sulis Therapeutics ApS (CVR 44445832) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR -167,138 and a net result of EUR -202,314. Equity in the 2024 report amounted to EUR -45,838. The company had 1 employee in the financial year.
- Gross Profit
- EUR -167,138
- Profit/Loss
- EUR -202,314
- Equity
- EUR -45,838
- Total Assets
- EUR 533,420
- Employees
- 1
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of June 27, 2024, Sten Verland has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Morten Døssing has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Martin Roelsgaard Jakobsen has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Christian Schetter has left the board of directors of Sulis Therapeutics ApS.
As of June 27, 2024, Regina Hodits has left the board of directors of Sulis Therapeutics ApS.
On June 27, 2024, the company changed its name from Selskabet af 21. november 2023 ApS to Sulis Therapeutics ApS.
As of May 23, 2024, CLAUS OLESEN HOLDING ApS is registered as an owner of Sulis Therapeutics ApS with an ownership share of 50%.
As of May 23, 2024, MR Jakobsen Holding ApS is registered as an owner of Sulis Therapeutics ApS with an ownership share of 15%.
As of May 23, 2024, is registered as an owner of Sulis Therapeutics ApS with an ownership share of 25%.
Sulis Therapeutics ApS has published its interim report for the period November 21, 2023 to December 31, 2023.
About Sulis Therapeutics ApS
Sulis Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Selskabet af 21. november 2023 ApS. The management consists of Claus Elsborg Olesen. The board consists of Sten Verland (chair), Claus Elsborg Olesen and Martin Roelsgaard Jakobsen. The company is owned by CLAUS OLESEN HOLDING ApS, MR Jakobsen Holding ApS and Shinka Life Sciences AB. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR -866,109 and a net result of EUR -892,687 compared with EUR -202,314 the year before. Equity in the 2025 report amounted to EUR -938,524.